| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Institut National de la Santé et de la Recherche Médicale, Unité 128, Institut Fédératif de Recherche 24 (J.C.O., P.M., M.-J.V., J.M.P.), Centre National de la Recherche Scientifique, 34293 Montpellier Cedex 05, France; Laboratoire de Pharmacologie et Toxicologie (F.L., T.P.), Institut National de la Recherche Agronomique, 31931 Toulouse, Cedex 9, France; Service de Chirurgie (J.M.F.), Hôpital Saint Eloi, 34295 Montpellier Cedex 05, France; and Service de Chirurgie Digestive (A.S.-C.), Hôpital Haut Levèque, 33600 Pessac, France
Address all correspondence and requests for reprints to: Jean Marc Pascussi, Institut National de la Santé et de la Recherche Médicale, Unité 128, Institut Fédératif de Recherche 24, Centre National de la Recherche Scientifique, 1919 Route de Mend, 34293 Montpellier Cedex 05, France. E-mail: pascussi{at}montp.inserm.fr.
SHP (small heterodimer partner, NR1I0) is an atypical orphan member of the nuclear receptor subfamily in that it lacks a DNA-binding domain. It is mostly expressed in the liver, where it binds to and inhibits the function of nuclear receptors. SHP is up-regulated by primary bile acids, through the activation of their receptor farnesoid X receptor, leading to the repression of cholesterol 7
-hydroxylase (CYP7
) expression, the rate-limiting enzyme in bile acid production from cholesterol. PXR (pregnane X receptor, NR1I2) is a broad-specificity sensor that recognizes a wide variety of synthetic drugs as well as endogenous compounds such as bile acid precursors. Upon activation, PXR induces CYP3A and inhibits CYP7
, suggesting that PXR can act on both bile acid synthesis and elimination. Indeed, CYP7
and CYP3A are involved in biochemical pathways leading to cholesterol conversion into primary bile acids, whereas CYP3A is also involved in the detoxification of toxic secondary bile acid derivatives. Here, we show that PXR is a target for SHP. Using pull-down assays, we show that SHP interacts with both murine and human PXR in a ligand-dependent manner. From transient transfection assays, SHP is shown to be a potent repressor of PXR transactivation. Furthermore, we report that chenodeoxycholic acid and cholic acid, two farnesoid X receptor ligands, induce up-regulation of SHP and provoke a repression of PXR-mediated CYP3A induction in human hepatocytes as well as in vivo in mice. These results reveal an elaborate regulatory cascade, tightly controlled by SHP, for both the maintenance of bile acid production and detoxification in the liver.
NURSA Molecule Pages Link:
This article has been cited by other articles:
![]() |
H. B. Hartman, S. J. Gardell, C. J. Petucci, S. Wang, J. A. Krueger, and M. J. Evans Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- and apoE-/- mice J. Lipid Res., June 1, 2009; 50(6): 1090 - 1100. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Hariparsad, X. Chu, J. Yabut, P. Labhart, D. P. Hartley, X. Dai, and R. Evers Identification of pregnane-X receptor target genes and coactivator and corepressor binding to promoter elements in human hepatocytes Nucleic Acids Res., March 1, 2009; 37(4): 1160 - 1173. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. B. Hartman, K. Lai, and M. J. Evans Loss of small heterodimer partner expression in the liver protects against dyslipidemia J. Lipid Res., February 1, 2009; 50(2): 193 - 203. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Matsubara, K. Yoshinari, K. Aoyama, M. Sugawara, Y. Sekiya, K. Nagata, and Y. Yamazoe Role of Vitamin D Receptor in the Lithocholic Acid-Mediated CYP3A Induction in Vitro and in Vivo Drug Metab. Dispos., October 1, 2008; 36(10): 2058 - 2063. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Callaghan, E. Crowley, S. Potter, and I. D. Kerr P-glycoprotein: So Many Ways to Turn It On J. Clin. Pharmacol., March 1, 2008; 48(3): 365 - 378. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Lemaire, C. Benod, V. Nahoum, A. Pillon, A.-M. Boussioux, J.-F. Guichou, G. Subra, J.-M. Pascussi, W. Bourguet, A. Chavanieu, et al. Discovery of a Highly Active Ligand of Human Pregnane X Receptor: A Case Study from Pharmacophore Modeling and Virtual Screening to "In Vivo" Biological Activity Mol. Pharmacol., September 1, 2007; 72(3): 572 - 581. [Abstract] [Full Text] [PDF] |
||||
![]() |
K.-G. Park, K.-M. Lee, H.-Y. Seo, J.-H. Suh, H.-S. Kim, L. Wang, K.-C. Won, H.-W. Lee, J.-Y. Park, K.-U. Lee, et al. Glucotoxicity in the INS-1 Rat Insulinoma Cell Line Is Mediated by the Orphan Nuclear Receptor Small Heterodimer Partner Diabetes, February 1, 2007; 56(2): 431 - 437. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Suh, J. Huang, Y.-Y. Park, H.-A Seong, D. Kim, M. Shong, H. Ha, I.-K. Lee, K. Lee, L. Wang, et al. Orphan Nuclear Receptor Small Heterodimer Partner Inhibits Transforming Growth Factor-beta Signaling by Repressing SMAD3 Transactivation J. Biol. Chem., December 22, 2006; 281(51): 39169 - 39178. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. D. Moore, S. Kato, W. Xie, D. J. Mangelsdorf, D. R. Schmidt, R. Xiao, and S. A. Kliewer International Union of Pharmacology. LXII. The NR1H and NR1I Receptors: Constitutive Androstane Receptor, Pregnene X Receptor, Farnesoid X Receptor {alpha}, Farnesoid X Receptor beta, Liver X Receptor {alpha}, Liver X Receptor beta, and Vitamin D Receptor Pharmacol. Rev., December 1, 2006; 58(4): 742 - 759. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. K. Iyer, Y.-H. Zhang, and E. R. B. McCabe Dosage-Sensitive Sex Reversal Adrenal Hypoplasia Congenita Critical Region on the X Chromosome, Gene 1 (DAX1) (NR0B1) and Small Heterodimer Partner (SHP) (NR0B2) Form Homodimers Individually, as Well as DAX1-SHP Heterodimers Mol. Endocrinol., October 1, 2006; 20(10): 2326 - 2342. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Li and J. Y. L. Chiang RIFAMPICIN INDUCTION OF CYP3A4 REQUIRES PREGNANE X RECEPTOR CROSS TALK WITH HEPATOCYTE NUCLEAR FACTOR 4{alpha} AND COACTIVATORS, AND SUPPRESSION OF SMALL HETERODIMER PARTNER GENE EXPRESSION Drug Metab. Dispos., May 1, 2006; 34(5): 756 - 764. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Aouabdi, G. Gibson, and N. Plant TRANSCRIPTIONAL REGULATION OF THE PXR GENE: IDENTIFICATION AND CHARACTERIZATION OF A FUNCTIONAL PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR {alpha} BINDING SITE WITHIN THE PROXIMAL PROMOTER OF PXR Drug Metab. Dispos., January 1, 2006; 34(1): 138 - 144. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Orans, D. G. Teotico, and M. R. Redinbo The Nuclear Xenobiotic Receptor Pregnane X Receptor: Recent Insights and New Challenges Mol. Endocrinol., December 1, 2005; 19(12): 2891 - 2900. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Li, M. Choi, K. Suino, A. Kovach, J. Daugherty, S. A. Kliewer, and H. E. Xu Structural and biochemical basis for selective repression of the orphan nuclear receptor liver receptor homolog 1 by small heterodimer partner PNAS, July 5, 2005; 102(27): 9505 - 9510. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. G. Yeo, Y.-G. Yoo, H.-S. Choi, Y. K. Pak, and M.-O. Lee Negative Cross-Talk between Nur77 and Small Heterodimer Partner and Its Role in Apoptotic Cell Death of Hepatoma Cells Mol. Endocrinol., April 1, 2005; 19(4): 950 - 963. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Li and J. Y. L. Chiang Mechanism of rifampicin and pregnane X receptor inhibition of human cholesterol 7{alpha}-hydroxylase gene transcription Am J Physiol Gastrointest Liver Physiol, January 1, 2005; 288(1): G74 - G84. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-Y. Kim, H.-J. Kim, K. T. Kim, Y.-Y. Park, H.-A Seong, K. C. Park, I.-K. Lee, H. Ha, M. Shong, S. C. Park, et al. Orphan Nuclear Receptor Small Heterodimer Partner Represses Hepatocyte Nuclear Factor 3/Foxa Transactivation via Inhibition of Its DNA Binding Mol. Endocrinol., December 1, 2004; 18(12): 2880 - 2894. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-Y. Kim, K. Chu, H.-J. Kim, H.-A Seong, K.-C. Park, S. Sanyal, J. Takeda, H. Ha, M. Shong, M.-J. Tsai, et al. Orphan Nuclear Receptor Small Heterodimer Partner, a Novel Corepressor for a Basic Helix-Loop-Helix Transcription Factor BETA2/NeuroD Mol. Endocrinol., April 1, 2004; 18(4): 776 - 790. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Stedman, G. Robertson, S. Coulter, and C. Liddle Feed-forward Regulation of Bile Acid Detoxification by CYP3A4: STUDIES IN HUMANIZED TRANSGENIC MICE J. Biol. Chem., March 19, 2004; 279(12): 11336 - 11343. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Shimamoto, J. Ishida, K. Yamagata, T. Saito, H. Kato, T. Matsuoka, K. Hirota, H. Daitoku, M. Nangaku, K. Yamagata, et al. Inhibitory Effect of the Small Heterodimer Partner on Hepatocyte Nuclear Factor-4 Mediates Bile Acid-induced Repression of the Human Angiotensinogen Gene J. Biol. Chem., February 27, 2004; 279(9): 7770 - 7776. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Handschin and U. A. Meyer Induction of Drug Metabolism: The Role of Nuclear Receptors Pharmacol. Rev., December 1, 2003; 55(4): 649 - 673. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |